I'm looking for

SGO’s government relations efforts support its mission through three strategic pillars:

Advocate

Lead national policy and payment reform to advance gynecologic cancer care.
SGO works to ensure policies, payment systems, and federal investments support equitable, high-quality cancer care and research.

Our advocacy priorities include:

  • Championing federal funding for prevention, screening, and patient education.
  • Securing increased Department of Defense and NIH funding for gynecologic cancer research.
  • Engaging coalitions to protect Medicare physician reimbursement and promote stability.
  • Advancing coding and payment policies so gynecologic oncology care is recognized and reimbursed accurately.
  • Expanding access to inclusive and equitable cancer care, particularly for underserved populations.

Optimize

Set quality standards and tools that improve outcomes and reduce disparities.
SGO supports the development of guidelines, quality benchmarks, and improvement initiatives that optimize patient care.

Current priorities include:

  • Defining high-quality gynecologic oncology care and building member awareness of quality measures.
  • Providing frameworks and resources that support member-driven quality improvement projects.

Empower

Support members with education, resources, and community across their careers.
SGO equips members to succeed in a changing healthcare environment with tools that support clinical excellence, practice sustainability, and career growth.

Key priorities include:

  • Providing coding and practice management education to strengthen reimbursement and compliance.
  • Expanding career development opportunities for gynecologic oncologists and the broader care team.

SGO STRATEGIC PLAN

SIGN-ON LETTERS

Government Relations Committees

The government relations committees guide SGO’s advocacy on national policy issues affecting gynecologic oncology. The three committees — Health and Legislative Affairs, Coding and Reimbursement, and Quality Care — provide a framework for monitoring federal policy, shaping future payment reforms, and exploring strategies to improve quality and access to care. These committees represent SGO’s commitment to advancing policies that support gynecologic oncologists, sustain research, and improve outcomes for patients.

nurses-working-at-station

Coding and Reimbursement

The Coding and Reimbursement Committee represents the interests of gynecologic oncologists on Medicare payment regulations, CPT code development, and other issues that impact coding, billing, and reimbursement. The committee provides expertise to SGO leadership on reimbursement policy, advances proposals for new and revised CPT codes in partnership with the American College of Obstetricians and Gynecologists (ACOG), and ensures visibility within the American Medical Association (AMA) CPT Editorial Panel and related national forums.

Quality Care Committee

The Quality Care Committee is focused on defining the role of quality in shaping the future of gynecologic oncology payment and developing resources to support member-driven quality improvement projects. By linking quality outcomes to fair reimbursement, the committee is working to align members around strategies that strengthen patient care and ensure sustainable practice. Through resource development and exploration of benchmarks and outcomes data, the committee is building the foundation for value-based care in gynecologic oncology.

aboutsgo
practicemanagement

Health and Legislative Affairs

The Health and Legislative Affairs Committee monitors federal legislative activity and leads advocacy on policies and programs that affect gynecologic oncology. The committee engages with policymakers, builds relationships across coalitions, and advances initiatives such as research funding and expanded access to high-quality gynecologic cancer care. Its work ensures that the voices of the gynecologic oncology care team and the patients they serve are represented in national policy decisions.

Interested participating in these initiatives?

Contact Carly Leon to Join the SGO Congressional Ambassadors Program

View Our Latest Congressional Briefing:  Advancing Innovation in Gynecologic Cancers

Presented by the Society of Gynecologic Oncology on February 13, 2025

Esteemed experts in clinical trials research discussed the public health burden of gynecologic cancers and highlighted the critical need for additional exploration that will lead to breakthroughs in treatment. View the recording to learn from leading voices dedicated to improving outcomes and driving progress in gynecologic cancer research and care.

Speakers:

  • Amanda Nickles Fader, MD, SGO Past President
  • Vanessa Hill, MFA, MPH, patient advocate
  • Warner Huh, MD, MSHA, SGO Past-President
  • Matthew Powell, MD, SGO President Elect I

woman-on-phone

Sign-on Letters

Below are the federal agency comment letters and national sign on letters that SGO has contributed to over the past six months.

 

View letters filed prior to the past six months here.

Join SGO Today

What you get out of membership changes your patient’s lives. What you give from your membership changes the world. Join your community today.

Become a Member

Recent Position Statements

With health care a constant political issue and technology overtaking even our imaginations, staying ahead of developments is more important than ever.

Jun 2, 2020

SGO Statement on Racism and Violence

Type: Position Statements
Type: Health Equity
Oct 1, 2016

Opioid Use in Gynecology Oncology; Balancing Efficacy, Accessibility and Safety: An SGO Clinical Practice Statement

Type: Position Statements
Type: Health Policy
Oct 1, 2016

Position Statement on Pelvic Examinations

Type: Position Statements
Type: Pelvic Examinations
Oct 1, 2014

Genetic Testing for Gynecologic Cancer

Type: Position Statements
Type: Genetics
Dec 1, 2013

SGO Position Statement: Morcellation

Type: Position Statements
Type: Morcellation
Dec 1, 2013

HPV Vaccination of Girls and Boys

Type: Position Statements
Type: Cervical CancerHPV
May 1, 2013

Multiplex Serum Testing for Women with Pelvic Mass

Type: Position Statements
Type: Ovarian Cancer
Mar 1, 2012

Cervical Cancer Screening Recommendations

Type: Position Statements
Type: Cervical Cancer
Jun 1, 2011

OCEANS Study Results

Type: Position Statements
Type: Ovarian Cancer
May 1, 2011

Role of HPV Testing and HPV Typing in Cervical Cancer Prevention and Detection

Type: Position Statements
Type: Cervical CancerHPV
Sep 1, 2010

Delivery of Palliative Care Services

Type: Position Statements
Type: Palliative Care
Jun 1, 2010

GOG 218 Phase III Trial Study Results

Type: Position Statements
Type: Ovarian Cancer
Jun 1, 2009

Use of CA125 for Monitoring Ovarian Cancer

Type: Position Statements
Type: Ovarian Cancer
Jun 1, 2010

Use of CA125 in Screening for Ovarian Cancer

Type: Position Statements
Type: Ovarian Cancer